141 citations,
September 2016 in “European Journal of Dermatology” Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.
1 citations,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
218 citations,
September 2012 in “Gastroenterology” Colorectal cancer development involves both genetic changes and epigenetic alterations like DNA methylation and microRNA changes.
131 citations,
September 2017 in “Molecular and Cellular Endocrinology” The document concludes that blocking the internal pathways that create androgens might help treat cancers that depend on sex hormones.
54 citations,
January 2023 in “Signal Transduction and Targeted Therapy” New therapies are being developed that target integrin pathways to treat various diseases.
35 citations,
May 2022 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” Androgens like testosterone are important hormones for both men and women, made differently in each sex and affecting the body by regulating genes and quick interactions with cell components.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
28 citations,
January 2016 in “Vitamins and hormones” Thymosin β4 helps improve skin healing and reduce scarring.
14 citations,
May 2012 in “Endocrine Research” The same hormone can affect gene expression differently in various tissues, which could lead to new treatments for conditions like hair loss.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
February 2024 in “Pharmaceutics” Microneedles with extracellular vesicles show promise for treating various conditions with targeted delivery.
81 citations,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
72 citations,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
7 citations,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
232 citations,
January 2013 in “Nature Cell Biology” Understanding where cancer cells come from helps create better prevention and treatment methods.
2 citations,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
12 citations,
October 2013 in “The Prostate” Dutasteride and finasteride affect different cell types differently.
9 citations,
September 2009 in “The Prostate” Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
45 citations,
April 2018 in “Nature Reviews Urology” Male genital development is driven by androgen signaling and understanding it could help address congenital anomalies.
5 citations,
May 2018 in “Therapeutic advances in drug safety” Androgen use may increase the risk of stroke, but more research is needed.
29 citations,
July 2013 in “The Journal of Sexual Medicine” Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
66 citations,
January 2001 in “Vitamins and hormones” Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.
23 citations,
January 2014 in “International Journal of Biological Sciences” African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.
108 citations,
February 2008 in “The Journal of urology/The journal of urology” Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
9 citations,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
27 citations,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
82 citations,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.